Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
Cinnamon Girl said
May 21, 2015
Hi guys, I was reading an article about that. It should prove a very beneficial arrangement for Achillon, and if it helps gets the drugs to market sooner then many more Hep C sufferers will be benefit too.
Your correct, in a couple of years when these two company's finish their clinical trials for their HCV combo killer their will still be millions of people world wide needing a better cure for the malady. But Gilead has quite a lead in this race so it will not be easy to catch up, thats why Achillion make a wise move in partnering with a larger Biotech company that can fund the much needed larger clinical trials.
matt
bubble said
May 21, 2015
It look's like J+J bought Achillion's Hep C anti viral drug for 1.1B. This sounds reminisent of when Pharmasset sold to Gilead their work and then teamed up with Bristol-Myers to make the cure known as Harvoni. Looks like J+J could squash Gilead in the future. I hope this speeds up things for all. The Phama industry is so cut throat. I know they are trying for a 4 week cure. Right now I am reading 100% cure for a group of 18 people. Follow the money, Pray for all.
angelseven said
May 19, 2015
Thanks you guys!!!!
mallani said
May 19, 2015
Hi Connie,
Matt has given some good links.
Achillion Pharmaceuticals may have good alternatives. Their antiprotease, ACH-1625 (now called Sovaprevir) has breakthrough status, and is pan-genotype. It is similar to MK-5172.
Their NS-5A inhibitor, ACH-3102, is second generation and is claimed to be effective against the RAV's that arise after Ledipasvir and Daclatasvir treatment failures. It is currently in Phase 2 Trials, and has achieved great results with only 6 and 8 weeks of combination treatment with Sovaldi. The patients were all Rx-naive and the numbers are small (18).
Achillion are also trialling their Sovaldi alternative, ACH-3422. This is claimed to be a very potent nucleoside NS-5B blocker.
It's too early to give an opinion of their drugs, but they will be an obvious choice for Harvoni failures if the great results continue.
We are now getting more data about the RAV's at NS-5A- they are obviously going to be a problem for some patients.
I'll give you a proper reply in 6-9 months. Cheers.
angelseven said
May 19, 2015
Hey Matt, I talked to my hepalogist office (Dr Galati) about this testing... they are really clueless, I showed them several of the tests that Quest does to check for sofosbuvir and ledipasvir resistance... they were not interested in this at all... I think I might have to switch back over to Baylor ... they have more research going on and you actually can see a real doctor... but it is kind of like a zoo there and hard to get anyone on the phone...
I guess there is the deep DNA testing, is this what you are referring to... no sense doing anything right til I know what the new meds are... I am not jumping into treatment in the first year the meds are released this time... as long as my fibrosis is low and I can wait...
This is complicated stuff and I am not nearly educated enough to comprehend it all!!!
Thanks, I am going to get my friend on here... she also relapsed following 12 weeks of harvoni... she was treatment naļve but higher viral load... maybe 6,000 ,,,.. she went through the same pattern I did... undetected until 4 weeks following EOT
Honestly, at first I thought maybe I did not do the harvoni long enough, but my gut feeling now is that I am resistant to it...
I think it will get to a point where they can test your blood and figure out the exact treatment for you with 100% accuracy... what ya think??
Hope you are doing well!!
Connie/angelseven
Matt Chris wrote:
Hey Connie
Thanks for the link, it good to see that your staying on top of the HCV treatment developments. I read about this also from the EASL conference, though it was a very small study number the results are very promising. As time passes and we see more real world data on Harvoni patients. In the coming months doctors and HCV treatments specialists will have to address the best way to handle relapsed patients.
There was a study released at the EASL ( Dr. Lawitz) on re-treatment on patients that failed Gilead's trials on Sofosbuvie & Ledipasvir (Harvoni) that had some interesting points, here is the link
http://www.natap.org/2015/EASL/EASL_26.htm and also
Connie I think I mentioned this before. but in case I have not, If I were you I would want to know if the cause of my relapse was by RAV's and if so what location so you know what future choices of treatment maybe your best option. It maybe that you did't develop any RAV's during the eight weeks and that it just was not a long enough treatment duration.
I my own 12 week DAA treatment relapse its showed via population sequencing no present RAV's. I know its a expense test but these types of lab tests will be more common in the coming years and with your good health status you may able to wait a year or so.
I know how you feel so hang in there your future has not been written yet.
matt
Matt Chris said
May 19, 2015
Hey Connie
Thanks for the link, it good to see that your staying on top of the HCV treatment developments. I read about this also from the EASL conference, though it was a very small study number the results are very promising. As time passes and we see more real world data on Harvoni patients. In the coming months doctors and HCV treatments specialists will have to address the best way to handle relapsed patients.
There was a study released at the EASL ( Dr. Lawitz) on re-treatment on patients that failed Gilead's trials on Sofosbuvie & Ledipasvir (Harvoni) that had some interesting points, here is the link
http://www.natap.org/2015/EASL/EASL_26.htm and also
Connie I think I mentioned this before. but in case I have not, If I were you I would want to know if the cause of my relapse was by RAV's and if so what location so you know what future choices of treatment maybe your best option. It maybe that you did't develop any RAV's during the eight weeks and that it just was not a long enough treatment duration.
I my own 12 week DAA treatment relapse its showed via population sequencing no present RAV's. I know its a expense test but these types of lab tests will be more common in the coming years and with your good health status you may able to wait a year or so.
I know how you feel so hang in there your future has not been written yet.
matt
angelseven said
May 19, 2015
OK, since I relapsed with Harvoni, I am trying to see what is the next best treatment down the road... this appears to be for relapsers
Malani, if you are out there I am wondering what you think about it??
Hi guys, I was reading an article about that. It should prove a very beneficial arrangement for Achillon, and if it helps gets the drugs to market sooner then many more Hep C sufferers will be benefit too.
Here`s the link...
http://hcvadvocate.blogspot.ca/2015/05/achillion-enters-into-worldwide.html
Hey Bubble
Your correct, in a couple of years when these two company's finish their clinical trials for their HCV combo killer their will still be millions of people world wide needing a better cure for the malady. But Gilead has quite a lead in this race so it will not be easy to catch up, thats why Achillion make a wise move in partnering with a larger Biotech company that can fund the much needed larger clinical trials.
matt
It look's like J+J bought Achillion's Hep C anti viral drug for 1.1B. This sounds reminisent of when Pharmasset sold to Gilead their work and then teamed up with Bristol-Myers to make the cure known as Harvoni. Looks like J+J could squash Gilead in the future. I hope this speeds up things for all. The Phama industry is so cut throat. I know they are trying for a 4 week cure. Right now I am reading 100% cure for a group of 18 people. Follow the money, Pray for all.
Thanks you guys!!!!
Hi Connie,
Matt has given some good links.
Achillion Pharmaceuticals may have good alternatives. Their antiprotease, ACH-1625 (now called Sovaprevir) has breakthrough status, and is pan-genotype. It is similar to MK-5172.
Their NS-5A inhibitor, ACH-3102, is second generation and is claimed to be effective against the RAV's that arise after Ledipasvir and Daclatasvir treatment failures. It is currently in Phase 2 Trials, and has achieved great results with only 6 and 8 weeks of combination treatment with Sovaldi. The patients were all Rx-naive and the numbers are small (18).
Achillion are also trialling their Sovaldi alternative, ACH-3422. This is claimed to be a very potent nucleoside NS-5B blocker.
It's too early to give an opinion of their drugs, but they will be an obvious choice for Harvoni failures if the great results continue.
We are now getting more data about the RAV's at NS-5A- they are obviously going to be a problem for some patients.
I'll give you a proper reply in 6-9 months. Cheers.
Hey Connie
Thanks for the link, it good to see that your staying on top of the HCV treatment developments. I read about this also from the EASL conference, though it was a very small study number the results are very promising. As time passes and we see more real world data on Harvoni patients. In the coming months doctors and HCV treatments specialists will have to address the best way to handle relapsed patients.
There was a study released at the EASL ( Dr. Lawitz) on re-treatment on patients that failed Gilead's trials on Sofosbuvie & Ledipasvir (Harvoni) that had some interesting points, here is the link
http://www.natap.org/2015/EASL/EASL_26.htm and also
http://www.healio.com/hepatology/hepatitis-c/news/online/%7Bb067e467-93a0-4853-83ce-
ab4b82d67aef%7D/ns5a-ravs-may-persist-through-96-weeks-after-ledipasvir-therapy#
Connie I think I mentioned this before. but in case I have not, If I were you I would want to know if the cause of my relapse was by RAV's and if so what location so you know what future choices of treatment maybe your best option. It maybe that you did't develop any RAV's during the eight weeks and that it just was not a long enough treatment duration.
I my own 12 week DAA treatment relapse its showed via population sequencing no present RAV's. I know its a expense test but these types of lab tests will be more common in the coming years and with your good health status you may able to wait a year or so.
I know how you feel so hang in there your future has not been written yet.
matt
OK, since I relapsed with Harvoni, I am trying to see what is the next best treatment down the road... this appears to be for relapsers
Malani, if you are out there I am wondering what you think about it??
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10130749.htm
Thanks, Connie/angelseven